Allergan (AGN -1.2%) net profit $312.9M vs $324.2M
Total specialty pharmaceuticals net sales +14%, total core medical devices +17%.
Guidance: 2014 EPS of $5.36-5.48 vs consensus of $5.46, and product revenues of $6.65-6.95B vs $6.78B; Q1 EPS of $1.09-1.12 vs $1.21 and product sales of $1.525-1.6B vs $1.6B.
Declares a Q4 dividend of $0.05 per share, payable on March 21, 2014 to stockholders of record on February 28, 2014. (PR)